| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 20,860 | 15,187 | ||
| General and administrative | 3,557 | 3,965 | ||
| Total operating expenses | 24,417 | 19,152 | ||
| Operating loss | -24,417 | -19,152 | ||
| Interest and investment income, net | 1,125 | 1,314 | ||
| Interest expense | 0 | 0 | ||
| Other (expense) income, net | -50 | 176 | ||
| Total other income, net | 1,075 | 1,490 | ||
| Net loss | -23,342 | -17,662 | ||
| Earnings per share, basic, total | -1.9 | -1.44 | ||
| Earnings per share, diluted | -1.9 | -1.44 | ||
| Weighted average number of shares outstanding, basic | 12,307,298 | 12,240,443 | ||
| Weighted average number of shares outstanding, diluted | 12,307,298 | 12,240,443 | ||
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)